Please assess the completion status of the following clinical trial:

Trial Title: The Use of the Hormone Kisspeptin in 'in Vitro Fertilisation' (IVF) Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 - 34 years~* Body mass index between 18 and 29 kg/m2~* Stable body weight for at least 3 months~* Normal early menstrual cycle follicular phase serum FSH concentration~* Serum anti-Mullerian hormone (AMH) \> 40pmol/L~* No more than one previous IVF treatment cycle~* Both ovaries intact~Exclusion Criteria:~History of any medical, psychological or other condition, or use of any medications, including over-the-counter products, which, in the opinion of the investigators, would either interfere with the study or potentially cause harm to the volunteer~* Without access at home to a telephone, or other factor likely to interfere with ability to participate reliably in the study~* Treatment with an investigational drug within the preceding 2 months~* Donated blood during the preceding 3 months or intention to do so before the end of the study~* Previous poor response to IVF treatment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 34 Years
- Healthy Volunteers: f

Study Arms:
- Kisspeptin-54, 1.6 single (Type: EXPERIMENTAL): Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 1.6 nmol/kg
- Kisspeptin-54, 3.2 single (Type: EXPERIMENTAL): Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 3.2 nmol/kg
- Kisspeptin-54, 6.4 single (Type: EXPERIMENTAL): Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 6.4 nmol/kg
- Kisspeptin-54, 12.8 single (Type: EXPERIMENTAL): Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 12.8 nmol/kg
- Kisspeptin-54 OHSS, 3.2 single (Type: EXPERIMENTAL): Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 3.2 nmol/kg
- Kisspeptin-54 OHSS, 6.4 single (Type: EXPERIMENTAL): Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 6.4 nmol/kg
- Kisspeptin-54 OHSS, 9.6 single (Type: EXPERIMENTAL): Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 9.6 nmol/kg
- Kisspeptin-54 OHSS, 12.8 single (Type: EXPERIMENTAL): Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 12.8 nmol/kg
- Kisspeptin-54 OHSS, 9.6 + 9.6 (Type: EXPERIMENTAL): Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a trigger injection of Kisspeptin, dose of 9.6 nmol/kg and a further injection of Kisspeptin, dose of 9.6 nmol/kg 10 hours later
- Kisspeptin-54 OHSS, 9.6 + saline (Type: EXPERIMENTAL): Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a trigger injection of Kisspeptin, dose of 9.6 nmol/kg and a further injection of saline10 hours later

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete